Top Ten most popular articles on Pharmafile.com this week
pharmafile | April 17, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, coronavirus, top 10
Hydroxychloroquine dominates the news as the potential COVID-19 treatment has gone through various trials. A Chinese study showed that the drug does not speed up the recovery of coronavirus while another in Brazil was suspended after 11 patients died after taking the anti-malaria treatment.
President Trump has continually touted it as a treatment for the virus, and there has been an increase in people abusing the drug.
In more general industry related news, Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis cause skin cancer, while Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with AstraZeneca UK back in 2017 for the development and commercialisation of two respiratory drugs for the treatment of chronic obstructive pulmonary disease (COPD).
As the R&D race against COVID-19 continues, AstraZeneca is poised to launch a global, multicentre clinical trial to test its approved blood cancer drug Calquence (acalabrutinib) in the treatment of exaggerated immune response, also known as a cytokine storm, in patients severely ill with life-threatening COVID-19 symptoms, with the goal of ultimately reducing mortality and necessity of assisted ventilation.
9. Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute
A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s patents.
8. Gilead’s promising COVID-19 drug remdesivir shows benefit in 68% of hospitalised patients
Gilead has provided an update on its ongoing efforts against the novel coronavirus, revealing data from a cohort analysis of its antiviral therapy remdesivir, one of the most promising treatments for patients hospitalised by COVID-19.
7. Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement
Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with AstraZeneca UK back in 2017 for the development and commercialisation of two respiratory drugs for the treatment of chronic obstructive pulmonary disease (COPD).
6. Pfizer and Eli Lilly defeat lawsuit over claims Viagra and Cialis cause cancer
Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis cause skin cancer.
5. New Chinese study shows Hydroxychloroquine does not speed up COVID-19 recovery
The anti-malaria drug hydroxychloroquine does not speed up recovery from COVID-19, according to a new Chinese study.
4. US reports increase in Hydroxychloroquine misuse
The American Association of Poison Control Centers (AAPCC) has said there has been an increase in people abusing the anti-malaria drug hydroxychloroquine, after being touted by President Donald Trump as a coronavirus treatment.
3. Fatal heart complications halt Brazilian study of chloroquine in treating COVID-19
A chloroquine study investigating its effects in treating the COVID-19 coronavirus in Brazil has been postponed for safety reasons.
2. Intermittent social distancing could last until 2022, according to a new study
Social distancing that has been put in place to stem the spread of COVID-19 coronavirus could be implemented up until 2022, according to new research.
1. Sanofi and GSK set aside rivalry with “unprecedented” COVID-19 vaccine partnership
Usual rivals Sanofi and GlaxoSmithKline have said they are to put aside competition with the forging of a new “unprecedented collaboration” in the pursuit of an adjuvanted vaccine against the COVID-19 pandemic.
Related Content
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive …
